Despite the popularity of methods relying on fluorescent proteins
Written byRandall C Willis
| 1 min read
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
SANTA BARBARA, Calif.—Despite the popularity of methods relying on fluorescent proteins like GFP, the development of these techniques is being hampered by the low quantum yield and rapid photobleaching properties of many of these proteins. Researchers at University of California, Santa Barbara and Pasadena's Caltech are trying to change this, however.
As reported in Nature Biotechnology, the scientists used structure-guided design and fluorescence activated cell sorting to create and identify improved versions of blue fluorescent protein (BFP). Of the 330,000 unique sequences they generated, the researchers isolated 20 colonies for further characterization. They found that many of the clones carried mutation known to improve brightness in other fluorescent proteins, but they also identified novel mutations.
They then selected two clones with particularly enhanced brightness and found that one, which they named Azurite, had a significantly higher quantum yield than the parental BFP. And when they expressed Azurite in mammalian cells at 37°C, they noted its photobleaching half-life improved 40-fold over BFP, making it particularly well suited for a variety of fluorescence-based screening methods.
This person does not yet have a bio.View Full Profile
